1. Curriculum Vitae, Feb-2016
Name: Wing Lam
Nationality: US permanent resident
Phone number: 203-6403016
Home Address: 1145 Chapel st, #601, New Haven, CT 06511, US
Office Address: 333 Cedar st. Yale University, School of Medicine, Department of
Pharmacology, B254, CT 06520, US
Email: lamwingyale@hotmail.com, wing.lam@yale.edu
EDUCATION
Ph.D. Supervisor: Prof. WF Fong, City University Of Hong Kong, 1995-1999.
Thesis: “Pharmacology of Dextran-conjugated Doxorubicin in Multidrug Resistant KB
cells”
BSc (Hons) Applied Biology (Molecular Biology Division), City University of Hong
Kong, 1995, 2nd class, upper division honors
Researchexperience
Associate Research Scientist in Dr. Yung-Chi Cheng’s lab. Department of Pharmacology.
Yale University.
1. Identifying active herbs for FXR, LXR, TGR5 for use of metabolic diseaseas.
2. Development of herbal formulation for the treatment of prostate cancer.
3.Screening of activators from herbal medicine for WNT/beta-catenin signaling for tissue
re-generation and embryonic cell growth (US Patent).
Identified compounds for potentiating Wnt signaling.
4. Development of PHY-906 (traditional Chinese medicine) as adjuvant for anti-cancer
chemotherapy. (collaboration with PhytoCeutica’s. Inc.)
Combination of Irinotecan and PHY906 for treatment of colon cancer, phase II clinical
trial.
Combination of Sorafenib and PHY906 for treatment of liver cancer, phase I clinical trial.
Demonstrate that PHY906 increase the antitumor activity of Irinotecan and Sorafenib in
vivo and PHY906 promote intestine recovery after Irinotecan treatment.
5. Development of enzymatic based phytochemical library from Chinese herbal medicine.
6. Development of L-configuration nucleoside analog (L-OddC, Troxacitabine) for cancer
treatment.
Prove that AP Endonuclease (APE1) is a key factor in cell to cause Troxacitabine resistant.
Troxacitabine which had been entered phase III clinical trial for AML.
Demonstrate that hypoxia can sensitize Troxacitabine in solid tumor.
7. Mitochondria dNTP transporter (a possible mechanism of mitochondrial DNA depletion
caused by anti-HIV dideoxynucleoside analogs).
Dispute the DNC is the dNTP transporter on mitochondrial inner membrane.

2. 8. Develop tylophorine analogs as anti-cancer compounds.
First demonstration of antitumor activity in vivo of tylophorine analogs. Discovery of the
anti-NF-kB activity of tylophorine analogs.
9. HBV reverse transcriptase activity.
Characterization of the effects of lamivudine, 3TC associated resistant mutation on HBV
reverse transcriptase activity.
10. Drugs interaction (i.e. synergistic effects of drug-drug interaction) analysis.
Post-doctoral follow in Dr. Yung-Chi Cheng’s lab. Department of Pharmacology. Yale
University. Research on HBV DNA polymerase and pharmacology of natural product. 1999-
2002.
Research assistant in Dr. SH Cheng’s lab. Department of Biology and Chemistry. City
University of Hong Kong. Research on differentiation gene expression (Micro cDNA array
analysis) and drug resistance induced by environmental stresses. 1999.
Discovery that Benezopyrene increase Lung resistant protein which could cause low-level
doxorubicin resistant.
Laboratory Assistant in Dr. Nora Tam’s environmental research lab. Department of Biology
and Chemistry. City University of Hong Kong. Research on mangrove’s plant and heavy
metal analysis. 1994-1995
Academic Conferences
1. 10th CGCM Meeting (Consortium for Globalization of Chinese Medicine) in
Shanghai, China, August-25 to 27, 2011. Panelist of the Bioinformatics and
Database (Application of "Omics" in TCM Research) Session.
2. 11th CGCM Meeting (Consortium for Globalization of Chinese Medicine) in
Macau, China, August-26 to 28. 2012. Panelist of the Cancer Chemotherapy
Session.
3. 12th CGCM Meeting (Consortium for Globalization of Chinese Medicine) in
Graz, Austria, August-27 to 29. 2013. Panelist of the Cancer Chemotherapy
Session.
4. 13th CGCM Meeting (Consortium for Globalization of Chinese Medicine) in
Beijing, China, August-25 to 28. 2014. Panelist of the Biological Activity
Session.
List of Publication
1. Tsou LK, Lara-Tejero M, RoseFigura J, Zhang ZJ, Wang YC, Yount JS, Lefebre M,
Dossa PD, Kato J, Guan F, Lam W, Cheng YC, Galán JE, Hang HC. Antibacterial
Flavonoids from Medicinal Plants Covalently Inactivate Type III Protein Secretion
Substrates. J Am Chem Soc. 2016 Feb 24;138(7):2209-18.
2. Wang J, Jiang Z, Lam W, Gullen EA, Yu Z, Wei Y, Wang L, Zeiss C, Beck A,
Cheng EC, Wu C, Cheng YC, Zhang Y. Study of Malformin C, a Fungal Source
Cyclic Pentapeptide, as an Anti-Cancer Drug. PLoS One. 2015 Nov
5;10(11):e0140069.
3. Lam W, Jiang Z, Guan F, Huang X, Hu R, Wang J, Bussom S, Liu SH, Zhao H, Yen

3. Y, Cheng YC. PHY906(KD018), an adjuvant based on a 1800-year-old Chinese
medicine, enhanced the anti-tumor activity of Sorafenib by changing the tumor
microenvironment. Sci Rep. 2015 Mar 30;5:9384.
4. Lam W, Liu SH, Jiang Z and Cheng YC. Lessons from the Development of the
Traditional Chinese Medicine formula, PHY906. Science. 2015 Jan;347: S43-S44.
5. Liu SH, Chuang WC, Lam W, Jiang Z, Cheng YC. Safety surveillance of traditional
chinese medicine: current and future. Drug Saf. 2015 Feb;38(2):117-28.
6. Lam W, Jiang Z, Guan F, Hu R, Liu SH, Chu E, Cheng YC. The number of intestinal
bacteria is not critical for the enhancement of antitumor activity and reduction of
intestinal toxicity of irinotecan by the Chinese herbal medicine PHY906 (KD018).
BMC Complement Altern Med. 2014 Dec 15;14:490.
7. Selvaraj S, Ghebremichael M, Li M, Foli Y, Langs-Barlow A, Ogbuagu A, Barakat
L, Tubridy E, Edifor R, Lam W, Cheng YC, Paintsil E. Antiretroviral therapy-
induced mitochondrial toxicity: potential mechanisms beyond polymerase-γ
inhibition. Clin Pharmacol Ther. 2014 Jul;96(1):110-20. Epub 2014 Mar 17.
8. Lam W, Bussom S, Jiang Z, Zhang W, Guan F, Liu SH, and Cheng YC. PHY906, a
Cancer Adjuvant Therapy, Differentially Affects Inflammation of Different Tissues.
A Book Chapter of Contributor Agreements for Inflammation, Oxidative Stress
and Cancer: Dietary Approaches for Cancer Prevention. CRC Press/Taylor &
Francis Group, LLC. August 14, 2013
9. Wang Y, Wong HC, Gullen EA, Lam W, Yang X, Shi Q, Lee KH, Cheng YC.
Cryptopleurine analogs with modification of e ring exhibit different mechanism to
rac-cryptopleurine and tylophorine. PLoS One. 2012;7(12):e51138. Epub 2012 Dec
10.
10. Tang HW, Wong MY, Lam W, Cheng YC, Che CM, Ng KM. Molecular histology
analysis by matrix-assisted laser desorption/ionization imaging mass spectrometry
using gold nanoparticles as matrix. Rapid Commun Mass Spectrom. 2011 Dec
30;25(24):3690-6.
11. Wang E, Bussom S, Chen J, Quinn C, Bedognetti D, Lam W, Guan F, Jiang Z, Mark
Y, Zhao Y, Stroncek DF, White J, Marincola FM, Cheng YC. Interaction of a
traditional Chinese Medicine (PHY906) and CPT-11 on the inflammatory process in
the tumor microenvironment. BMC Med Genomics. 2011 May 11;4:38.
12. Hu R, Lam W, Hsu CH, Cheng YC. UMP/CMPK is not the critical enzyme in the
metabolism of pyrimidine ribonucleotide and activation of deoxycytidine analogs in
human RKO cells. PLoS One. 2011 May 3;6(5):e19490.
13. Leung CH, Chan DS, Man BY, Wang CJ, Lam W, Cheng YC, Fong WF, Hsiao WL,
Ma DL. Simple and convenient G-quadruplex-based turn-on fluorescence assay for
3' → 5' exonuclease activity. Anal Chem. 2011 Jan 15;83(2):463-6. Epub 2010 Nov
29.
14. Paintsil E, Dutschman GE, Hu R, Grill SP, Wang CJ, Lam W, Li FY, Ghebremichael
M, Northrup V, Cheng YC. Determinants of individual variation in intracellular
accumulation of anti-HIV nucleoside analog metabolites. Antimicrob Agents
Chemother. 2011 Feb;55(2):895-903. Epub 2010 Nov 15.
15. Lam W, Bussom S, Guan F, Jiang Z, Zhang W, Gullen EA, Liu SH, Cheng YC. The
Four-Herb Chinese Medicine PHY906 Reduces Chemotherapy-Induced
Gastrointestinal Toxicity. Science Translation Medicine. 2010 Aug-18.
16. Zhang W, Saif MW, Dutschman GE, Li X, Lam W, Bussom S, Jiang Z, Ye M, Chu
E, Cheng YC. Identification of chemicals and their metabolites from PHY906, a
Chinese medicine formulation, in the plasma of a patient treated with irinotecan and

4. PHY906 using liquid chromatography/tandem mass spectrometry (LC/MS/MS). J
Chromatogr A. 2010 Sep 10;1217(37):5785-93. Epub 2010 Jul 21.
17. Leung CH, Lam W, Ma DL, Gullen EA, Cheng YC. Butyrate mediates nucleotide-
binding and oligomerisation domain (NOD) 2-dependent mucosal immune responses
against peptidoglycan. Eur J Immunol. 2009 Dec;39(12):3529-37.
18. Wang CJ, Lam W, Bussom S, Chang HM, Cheng YC. TREX1 acts in degrading
damaged DNA from drug-treated tumor cells. DNA Repair (Amst). 2009 Oct
2;8(10):1179-89. Epub 2009 Jul 18.
19. McNeill DR, Lam W, DeWeese TL, Cheng YC, Wilson DM 3rd. Impairment of
APE1 function enhances cellular sensitivity to clinically relevant alkylators and
antimetabolites. Mol Cancer Res. 2009 Jun;7(6):897-906. Epub 2009 May 26.
20. Lam W, Bussom S, Cheng YC. Effect of hypoxia on the expression of
phosphoglycerate kinase and antitumor activity of troxacitabine and gemcitabine in
non-small cell lung carcinoma. 2009 Feb;8(2):415-23. Epub 2009 Feb 10.
21. Paintsil E, Dutschman GE, Hu R, Grill SP, Lam W, Baba M, Tanaka H, Cheng YC.
Intracellular Metabolism and Persistence of the Anti-Human Immunodeficiency
Virus Activity of 2', 3'-Didehydro-3'-Deoxy-4'- Ethynylthymidine, A Novel
Thymidine Analog. Antimicrob Agents Chemother. 2007 Aug 27.
22. Lam W, Leung CH, Bussom S and Cheng YC. The Impact of Hypoxic Treatment
on The Expression of PGK , APE-1 and The Cytotoxicity of Troxacitabine (L-OddC)
and Gemcitabine (dFdC). “Mol Pharmacol” Published June 12, 2007.
23. Rodrigues MA, Gomes DA, Leite MF, Grant W, Zhang L, Lam W, Cheng YC,
Bennett AM, Nathanson MH. Nucleoplasmic calcium is required for cell
proliferation. J Biol Chem. 2007 Jun 8;282(23):17061-8. Epub 2007 Apr 9
24. Leung CH, Grill SP, Lam W, Gao W, Sun HD, Cheng YC. Related Articles, Links
Eriocalyxin B inhibits NF-{kappa}B activation by interfering with the binding of
both p65 and p50 to the response element in a non-competitive manner. Mol
Pharmacol. 2006 Dec;70(6):1946-55. Epub 2006 Aug 29.
25. Lam W, Park SY, Leung CH, Cheng YC. Apurinic/apyrimidinic endonuclease-1
protein level is associated with the cytotoxicity of L-configuration deoxycytidine
analogs (troxacitabine and beta-L-2',3'-dideoxy-2',3'-didehydro-5-fluorocytidine)
but not D-configuration deoxycytidine analogs (gemcitabine and beta-D-
arabinofuranosylcytosine). Mol Pharmacol. 2006 May;69(5):1607-14. Epub 2006
Feb 15.
26. Leung CH, Grill SP, Lam W, Han QB, Sun HD, Cheng YC. Novel Mechanism of
Inhibition of Nuclear Factor-{kappa}B DNA-Binding Activity by Diterpenoids
Isolated from Isodon rubescens. Mol Pharmacol. 2005 Aug;68(2):286-97. Epub
2005 May 4
27. Hu R, Li L, Degreve B, Dutschman GE, Lam W, Cheng YC. Behavior of
Thymidylate Kinase toward Monophosphate Metabolites and Its Role in the
Metabolism of 1-(2'-Deoxy-2'-Fluoro-{beta}-L-Arabinofuranosyl)-5-Methyluracil
(Clevudine) and 2',3'-Didehydro-2',3'-Dideoxythymidine in Cells. Antimicrob
Agents Chemother. 2005 May;49(5):2044-2049.
28. Lam W, Chen C, Ruan S, Leung CH, Cheng YC. Expression of deoxynucleotide
carrier is not associated with the mitochondrial DNA depletion caused by anti-HIV
dideoxynucleoside analogs and mitochondrial dNTP uptake. Mol Pharmacol. 2005
Feb;67(2):408-16. Epub 2004 Nov 11.
29. Lam W, Li Y, Liou JY, Dutschman GE, Cheng YC. Reverse Transcriptase Activity
of Hepatitis B Virus (HBV) DNA Polymerase within Core Capsid: Interaction with

5. Deoxynucleoside Triphosphates and Anti-HBV L-Deoxynucleoside Analog
Triphosphates. Mol Pharmacol. 2004 Feb;65(2):400-6.
30. Gao W*, Lam W*, Zhong S, Kaczmarek C, Baker DC, Cheng YC. Novel mode of
action of tylophorine analogs as antitumor compounds. Cancer Res. 2004 Jan
15;64(2):678-88. W. Gao and W. Lam contributed equally to this work.
31. Krishnan P, Gullen EA, Lam W, Dutschman GE, Grill SP, Cheng YC. Novel role
of 3-phosphoglycerate kinase, a glycolytic enzyme, in the activation of L-nucleoside
analogs, a new class of anticancer and antiviral agents. J Biol Chem. 2003 Sep
19;278(38):36726-32. Epub 2003 Jul 16.
32. Liou JY, Dutschman GE, Lam W, Jiang Z, Cheng YC. Characterization of human
UMP/CMP kinase and its phosphorylation of D- and L-form deoxycytidine analogue
monophosphates. Cancer Res. 2002 Mar 15;62(6):1624-31.
33. Krishnan P, Fu Q, Lam W, Liou JY, Dutschman G, Cheng YC. Phosphorylation of
pyrimidine deoxynucleoside analog diphosphates: selective phosphorylation of L-
nucleoside analog diphosphates by 3-phosphoglycerate kinase.. J Biol Chem 2002
Feb 15;277(7):5453-5459.
34. Park SY, Lam W, Cheng Yc YC. X-ray Repair Cross-Complementing Gene I
Protein Plays an Important Role in Camptothecin Resistance. Cancer Res 2002 Jan
15;62(2):459-65
35. Leung CH, Lam W, Zhuang WJ, Wong NS, Yang MS, Fong WF. PKCdelta-
dependent deubiquitination and stabilization of Gadd45 in A431 cells overexposed
to EGF. Biochem Biophys Res Commun 2001 Jul 13;285(2):283-8.
36. Fong WF, Leung CH, Lam W, Wong NS, Cheng SH. Epidermal growth factor
induces Gadd45 (growth arrest and DNA damage inducible protein) expression in
A431 cells. Biochim Biophys Acta (Gene Structure and Expression) 2001 Jan
26;1517(2):250-6
37. Lam W, Leung CH, Chan HL, Fong WF. Toxicity and DNA binding of dextran-
doxorubicin conjugates in multidrug-resistant KB-V1 cells: optimization of dextran
size. Anticancer Drugs. 2000 Jun;11(5):377-84.
38. Cheng SH, Lam W, Lee AS, Fung KP, Wu RS, Fong WF. Low-level doxorubicin
resistance in benzo[a]pyrene-treated KB-3-1 cells is associated with increased LRP
expression and altered subcellular drug distribution. Toxicol Appl Pharmacol. 2000
Apr 15;164(2):134-42.
39. Che CM, Yang M, Wong KH, Chan HL and Lam W. Platinium (II) Complexes of
Dipyridophenazine as Metallointercalators for DNA and Potent Cytotoxic Agents
Carcinoma Cell Lines. Chem. Eur. J. 1999 5(11):3350-3356.
40. Lam W, Chan HL, Yang M, Cheng S, Fong W. Synergism of energy starvation and
dextran-conjugated doxorubicin in the killing of multidrug-resistant KB carcinoma
cells. Anticancer Drugs. 1999 Feb;10(2):171-8.
41. Yang M, Chan HL, Lam W, Fong WF. Cytotoxicity and DNA binding
characteristics of dextran-conjugated doxorubicins. Biochim Biophys Acta.
(General Subjects) 1998 May 8;1380(3):329-35.
42. Fong WF, Lam W, Yang M, Wong JT. Partial synergism between dextran-
conjugated doxorubicin and cancer drugs on the killing of multidrug resistant KB-
V1 cells. Anticancer Res. 1996 Nov-Dec;16(6B):3773-8.